Deleted Tweets From Scott Gottlieb, R-D.C.

#FDA NEWS: Optical coherence tomography (OCT) devices are important for helping manage eye diseases. A new pilot program helps OCT device manufacturers understand #FDA premarket performance testing recommendations and apply them in an interactive format https://t.co/4GyI3zeQVD

#FDA’s recent draft guidance for medical devices provides updated cybersecurity recommendations for manufacturers on how they can better protect products against different cybersecurity risks from ransomware to a catastrophic attack on a health system https://t.co/RRrRxF60vi https://t.co/7aXQAeUmiU

RT @SeemaCMS: We are at an age of a digital revolution. Focusing our healthcare system around the patient will allow us to have a… https://t.co/UiOy2BMe0i

RT @FDAWomen: Today we look forward to joining #ResearchDiversity Day. Follow along and join in the conversation. https://t.co/hfmG7P2zwe QT @NIH: Welcome to #ResearchDiversity Day! We’ll be sharing resources, researcher videos and testimonials, funding opportun… https://t.co/Ch8sthd90K)

#FDA’s public hearing on biologics competition and innovation resulted in numerous comments from many different stakeholders. FDA is using these comments to target high-priority areas of new policy development and outreach to promote Biosimilars access.

RT @FDASpox: Watch @SGottliebFDA at a joint #FDA/USDA meeting today discussing the potential hazards, oversight, labeling of cel… https://t.co/HG2TUNcHpu

By making the development and review of biosimilars more efficient, predictable and transparent; the #FDA can facilitate more competition among biologics and help bring down the cost of these important therapies, promoting patient access and advancing public health goals.

RT @FDA_Track: Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to advance new ways to increase the avail… https://t.co/MjLhgmGXbt

RT @FDAMedia: Statement from FDA Commissioner @SGottliebFDA on agency’s efforts to advance new ways to increase the availability… https://t.co/PGFTmuhZFZ

As part of its Biosimilars Action Plan, #FDA is developing additional guidance on the development and approval of biosimilar and interchangeable products. We’ll soon be updating our biosimilars “Q&A” guidance, that addresses questions that may arise during biosimilar development.

RT @davidmwessel: FDA approving wave of generic drugs to lower prices https://t.co/BTfBWKUs4x

With the number of overdose deaths from prescription an illicit opioids doubling from 21,089 in 2010 to 42,249 in 2016, it’s critical we continue to tackle this human tragedy from all fronts – including, and importantly, looking at new ways to increase availability of naloxone.

THREAD: As part of efforts to advance new ways to increase availability of naloxone as one means for reducing opioid overdose deaths, #FDA today announced it'll be holding a 2-day advisory committee meeting in Dec. to solicit input, advice on strategies https://t.co/C8p0PR4l19 https://t.co/fc5nuFYSAi

#FDA is taking new steps to lower costs of generic drug development; increase high-value generic approvals that benefit sponsors and patients; and improve the economics of generic development to foster competition, reduce barriers to entry, improve access: https://t.co/FE8qMrqxWa

RT @FDAWomen: FDA tackled the question of “What is enough?” when determining participation of women in cardiovascular disease cli… https://t.co/igNmEF9KKi

As part of CDRH’s continuing efforts to assure the safety and effectiveness of medical devices, #FDA is holding a public workshop on December 10-11 to discuss aspects of device servicing and remanufacturing. https://t.co/D0z9Zo8wNw https://t.co/rlK7ELXEva

We look forward to this important discussion on ways to make naloxone more available. We’re committed working with stakeholders across this country to combat the staggering human and economic toll created by opioid abuse and addiction. MY STATEMENT TODAY: https://t.co/C8p0PR4l19

RT @FDASpox: Been following naloxone? Read @SGottliebFDA’s statement on #FDA’s efforts to advance new ways to increase the avail… https://t.co/nTqMgtLBUl

#FDA continues to advance efforts to crack down on illegal opioids being sold online and shipped through mail facilities https://t.co/37TAL8KD22

The #FDA is considering whether naloxone should be required to be co-prescribed with certain opioids; and what other new steps can help promote more widespread access to naloxone among patients, providers, families, and other first responders. https://t.co/F55ZHJmYu2

#FDA NEWS: Optical coherence tomography (OCT) devices are important for helping manage eye diseases. A new pilot program helps OCT device manufacturers understand #FDA premarket performance testing recommendations and apply them in an interactive format https://t.co/4GyI3zeQVD

#FDA’s recent draft guidance for medical devices provides updated cybersecurity recommendations for manufacturers on how they can better protect products against different cybersecurity risks from ransomware to a catastrophic attack on a health system https://t.co/RRrRxF60vi https://t.co/7aXQAeUmiU

RT @SeemaCMS: We are at an age of a digital revolution. Focusing our healthcare system around the patient will allow us to have a… https://t.co/UiOy2BMe0i

RT @FDAWomen: Today we look forward to joining #ResearchDiversity Day. Follow along and join in the conversation. https://t.co/hfmG7P2zwe QT @NIH: Welcome to #ResearchDiversity Day! We’ll be sharing resources, researcher videos and testimonials, funding opportun… https://t.co/Ch8sthd90K)

#FDA’s public hearing on biologics competition and innovation resulted in numerous comments from many different stakeholders. FDA is using these comments to target high-priority areas of new policy development and outreach to promote Biosimilars access.

RT @FDASpox: Watch @SGottliebFDA at a joint #FDA/USDA meeting today discussing the potential hazards, oversight, labeling of cel… https://t.co/HG2TUNcHpu

By making the development and review of biosimilars more efficient, predictable and transparent; the #FDA can facilitate more competition among biologics and help bring down the cost of these important therapies, promoting patient access and advancing public health goals.

RT @FDA_Track: Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to advance new ways to increase the avail… https://t.co/MjLhgmGXbt

RT @FDAMedia: Statement from FDA Commissioner @SGottliebFDA on agency’s efforts to advance new ways to increase the availability… https://t.co/PGFTmuhZFZ

As part of its Biosimilars Action Plan, #FDA is developing additional guidance on the development and approval of biosimilar and interchangeable products. We’ll soon be updating our biosimilars “Q&A” guidance, that addresses questions that may arise during biosimilar development.

RT @davidmwessel: FDA approving wave of generic drugs to lower prices https://t.co/BTfBWKUs4x

With the number of overdose deaths from prescription an illicit opioids doubling from 21,089 in 2010 to 42,249 in 2016, it’s critical we continue to tackle this human tragedy from all fronts – including, and importantly, looking at new ways to increase availability of naloxone.

THREAD: As part of efforts to advance new ways to increase availability of naloxone as one means for reducing opioid overdose deaths, #FDA today announced it'll be holding a 2-day advisory committee meeting in Dec. to solicit input, advice on strategies https://t.co/C8p0PR4l19 https://t.co/fc5nuFYSAi

#FDA is taking new steps to lower costs of generic drug development; increase high-value generic approvals that benefit sponsors and patients; and improve the economics of generic development to foster competition, reduce barriers to entry, improve access: https://t.co/FE8qMrqxWa

RT @FDAWomen: FDA tackled the question of “What is enough?” when determining participation of women in cardiovascular disease cli… https://t.co/igNmEF9KKi

As part of CDRH’s continuing efforts to assure the safety and effectiveness of medical devices, #FDA is holding a public workshop on December 10-11 to discuss aspects of device servicing and remanufacturing. https://t.co/D0z9Zo8wNw https://t.co/rlK7ELXEva

We look forward to this important discussion on ways to make naloxone more available. We’re committed working with stakeholders across this country to combat the staggering human and economic toll created by opioid abuse and addiction. MY STATEMENT TODAY: https://t.co/C8p0PR4l19

RT @FDASpox: Been following naloxone? Read @SGottliebFDA’s statement on #FDA’s efforts to advance new ways to increase the avail… https://t.co/nTqMgtLBUl

#FDA continues to advance efforts to crack down on illegal opioids being sold online and shipped through mail facilities https://t.co/37TAL8KD22

The #FDA is considering whether naloxone should be required to be co-prescribed with certain opioids; and what other new steps can help promote more widespread access to naloxone among patients, providers, families, and other first responders. https://t.co/F55ZHJmYu2